You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.ExpreS2ion Biotechnologies will release its 2023 year-end results on 8 February 2024. Later the same day at 10:00, ExpreS2ion Biotechnologies’ CFO Keith Alexander will take a deeper dive into the results and achievements in a virtual live event.During 2023, ExpreS2ion Biotechnologies announced a review of its strategy, pipeline, and organization to further advance in the company’s exploratory pipeline and technology platforms. In Q4 2023, we saw the new strategy being carried out with the company together with partners being awarded a grant to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate. This is a first strong signal of the new strategy direction that will leverage their platform to advance assets with shorter development timelines and less costly paths to value creation. Besides the recent quarter’s financial results and a look into 2024, we expect that the attention in the event could be directed towards the progress in its strategy chance.ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 11.15 23 January 2024.